Cargando…

A comparison of US and Australian men’s values and preferences for PSA screening

BACKGROUND: Patient preferences derived from an assessment of values can help inform the design of screening programs, but how best to do so, and whether such preferences differ cross-nationally, has not been well-examined. The objective of this study was to compare the values and preferences of Aus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howard, Kirsten, Brenner, Alison T, Lewis, Carmen, Sheridan, Stacey, Crutchfield, Trisha, Hawley, Sarah, Nielsen, Matthew E, Pignone, Michael P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852221/ https://www.ncbi.nlm.nih.gov/pubmed/24093428 http://dx.doi.org/10.1186/1472-6963-13-388

Ejemplares similares

Older adults’ preferences for colorectal cancer-screening test attributes and test choice
por: Kistler, Christine E, et al.
Publicado: (2015)

What is the effect of a decision aid on knowledge, values and preferences for lung cancer screening? An online pre–post study
por: Clark, Stephen D, et al.
Publicado: (2021)

Getting patients in the door: medical appointment reminder preferences
por: Crutchfield, Trisha M, et al.
Publicado: (2017)

Primary goals, information-giving and men’s understanding: a qualitative study of Australian and UK doctors’ varied communication about PSA screening
por: Pickles, Kristen, et al.
Publicado: (2018)

Using a discrete choice experiment to inform the design of programs to promote colon cancer screening for vulnerable populations in North Carolina
por: Pignone, Michael P, et al.
Publicado: (2014)

The COMPASs Study: Community Preferences for Prostate cAncer Screening. Protocol for a quantitative preference study
por: Howard, Kirsten, et al.
Publicado: (2012)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Association between PSA values and surveillance quality after prostate cancer surgery
por: Chapman, Christina Hunter, et al.
Publicado: (2019)

The uptake and effect of a mailed multi-modal colon cancer screening intervention: A pilot controlled trial
por: Lewis, Carmen L, et al.
Publicado: (2008)

The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study
por: Clements, Alison, et al.
Publicado: (2007)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5–9.9 ng ml(−1)
por: Huang, Ma-Ping, et al.
Publicado: (2022)

Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer
por: Tang, Qionghua, et al.
Publicado: (2022)

Predictors of PSA Screening Among Men Over 40 Years of Age Who Had Ever Heard about PSA
por: Seo, Hyung Seok, et al.
Publicado: (2010)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

The effect of offering different numbers of colorectal cancer screening test options in a decision aid: a pilot randomized trial
por: Griffith, Jennifer M, et al.
Publicado: (2008)

The Association between Prostate-Specific Antigen Velocity (PSAV), Value and Acceleration, and of the Free PSA/Total PSA Index or Ratio, with Prostate Conditions
por: Flores-Fraile, María-Carmen, et al.
Publicado: (2020)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Usefulness of Total PSA Value in Prostate Diseases Diagnosis
por: Prcic, Alden, et al.
Publicado: (2016)

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy
por: Agnihotri, Shalini, et al.
Publicado: (2014)

Identifying men affected by changes in PSA screening in the COVID-19 pandemic
por: Bass, E.J., et al.
Publicado: (2022)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Contribution of allelic variability in prostate specific antigen (PSA) & androgen receptor (AR) genes to serum PSA levels in men with prostate cancer
por: Chavan, Sushant V., et al.
Publicado: (2014)

The effect of the frequency and duration of prostate specific antigen (PSA) measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer
por: Paller, CJ, et al.
Publicado: (2013)

Characteristics of α2,3‐sialyl N‐glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level
por: Yoneyama, Tohru, et al.
Publicado: (2021)

The impact of a decision aid about heart disease prevention on patients' discussions with their doctor and their plans for prevention: a pilot randomized trial
por: Sheridan, Stacey L, et al.
Publicado: (2006)

Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey
por: Hutchins, Robert, et al.
Publicado: (2015)

US Immigration paths for scientific researchers: Part 3
por: Pignone, Marco
Publicado: (2020)

Comparison of percentage free PSA, MRI and GaPSMA PET scan for diagnosing cancer prostate in men with PSA between 4 and 20 ng/ml
por: Kumar, Niraj, et al.
Publicado: (2019)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Low‐Dose‐Rate Prostate Brachytherapy (LDR‐PB) adopts postsurgical PSA value for definition of cure
por: Uribe, Jennifer, et al.
Publicado: (2020)

Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?
por: Busato, W. F. S., et al.
Publicado: (2015)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy in clinically significant prostate cancer detection in patients with biopsy-naïve men according to PSA levels: A propensity score matching analysis
por: Byun, Hye J., et al.
Publicado: (2022)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

The Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70
por: Casey, R. G., et al.
Publicado: (2012)

Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?
por: Just, Jasmine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u0b8nugvmr4l8n724kqelqpi2v